Novartis AG (NVS)
| Market Cap | 209.06B |
| Revenue (ttm) | 49.88B |
| Net Income (ttm) | 7.96B |
| Shares Out | 2.25B |
| EPS (ttm) | 3.48 |
| PE Ratio | 26.64 |
| Forward PE | 14.81 |
| Dividend | $3.40 |
| Dividend Yield | 3.67% |
| Trading Day | June 11 |
| Last Price | $92.69 |
| Previous Close | $93.50 |
| Change ($) | -0.81 |
| Change (%) | -0.87% |
| Day's Open | 93.26 |
| Day's Range | 92.53 - 93.26 |
| Day's Volume | 1,379,723 |
| 52-Week Range | 74.07 - 94.72 |
Of the equities that make up the S&P 500, only seven have market caps larger than $200 billion and pay a dividend yield of at least 3%.
Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual Co...
Novartis plans to close a plant in the southern Swiss town of Locarno, the drugmaker said on Wednesday, citing falling demand for testing products.
Novartis CEO on new cancer therapy programs
CNBC's Meg Tirrell talks to Dr. Vasant Narasimhan, CEO of Novartis, about his company's new cancer therapy, which uses targeted microdoses of radiation to combat cancer. For access to live and exclusive...
Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.
Novartis AG (NYSE: NVS) announced data from Phase 2 trial evaluating iptacopan (LNP023) in rare kidney disease IgA nephropathy (IgAN). Data were presented at the 58th ERA-EDTA Congress.
Basel, June 0 6 , 20 2 1 — Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in t...
Novartis AG (NYSE: NVS) reported the final analysis from the NETTER-1 phase 3 study comparing Lutathera plus 30 mg Sandostatin LAR (octreotide) to 60 mg octreotide LAR in patients with midgut neuroendoc...
Novartis (NVS) posts results from a late-stage study on radioligand therapy at the 2021 ASCO.
Basel, June 4, 2021 — Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta® (capmatinib) in adult pati...
Basel, June 4, 2021 — Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall surv...
Novartis AG (NYSE: NVS) has announced results from Phase 3 VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) in patients with progressive PSMA-posi...
Basel, June 3, 2021 — Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated signifi...
Here's one genetics play that you might want to put on your radar.
Basel, June 2, 2021 — Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients with relapsed or refractory (r/r) foll...
Novartis AG (NYSE: NVS) said that the Phase 3 JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing a significantly longer time to worsening of symptoms compared to placebo in ped...
The FDA has approved Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older and are candidates for systemic therapy or ph...
Basel, June 2, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx® (secukinumab) sig...
Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after more frequent dosing intervals were asso...
Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
Novartis AG (NYSE: NVS) along with Molecular Partners AG (OTC: MLLCF) is kicking off a Phase 2/3 EMPATHY study of DARPin therapeutic candidate, ensovibep (MP0420), to treat COVID-19. The program is inve...
Basel, May 27, 2021 — Novartis and Molecular Partners announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovi...
Basel, May 19, 2021 — Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 American Society of ...
The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG's (NYSE: NVS) Sandoz...
Novartis AG (NYSE: NVS) revealed details on Phase 3 PARADISE-MI trial evaluating Entresto (sacubitril/valsartan) compared with ramipril in a contemporary acute myocardial infarction (AMI) population. Da...
The following three stocks may be of interest to dividend investors, as they are offering much higher dividend yields than the S&P 500 Index. The benchmark index's dividend yields 1.38% as of Friday, Ap...
Novartis AG (NYSE: NVS) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to one-year...
Basel, May 1, 2021 — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular e...
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during the first quarter of 2021, which ended on March 31.
Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.
It was partially because of COVID-19.
Novartis earnings and revenue came in below first-quarter estimates, with the Swiss drug giant guiding to modest 2021 growth. Novartis stock edged lower.
A Milan judge on Tuesday indicted the Italian units of Novartis and Bayer on charges of operating a scheme to cheat the regional public health service in Lombardy, legal and judicial sources said.
Novartis AG (NYSE: NVS) Q1 core net income dropped 4% Y/Y, as COVID-19 related lockdowns and disruptions around the globe hit demand. Novartis missed earnings and sales expectations as the pandemic hit ...
Innovative medicines business returning to growth, Novartis CEO says
Novartis CEO Vas Narasimhan discusses the pharmaceutical company's first-quarter earnings and the outlook for drug approvals in 2021.
Novartis CEO: Health care systems are rebounding in U.S.
Novartis CEO Vas Narasimhan discusses the return of health care systems following the height of the coronavirus pandemic and the pharma giant's M&A strategy for 2021.
Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference ...
Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%, missing analyst expectations, as COVID-19 related lockdowns and disruptions around the globe hit demand.
Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.
These brand-name companies with $200 billion-plus market caps still have plenty of gas in the tank.
Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.
Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million...
Arix Bioscience PLC (LON:ARIX) said its portfolio company Artios Pharma Limited, in which it owns a 12.4% stake, has agreed a global research collaboration with Swiss pharma giant Novartis to create a n...
Just a week after acing Phase 3 study evaluating radioligand therapy in prostate cancer, Novartis AG (NYSE: NVS) is licensing the rights to develop and commercialize treatments based on a library of rad...
The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.
Johnson & Johnson's (NYSE:JNJ) 2020 revenue topped all pharmaceutical companies, according to rankings published by Fierce Pharma.
Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclero...
Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents inclu...
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to... [Read more...]
| Industry Drug Manufacturers-General | IPO Date Nov 18, 1991 |
| Stock Exchange NYSE | Ticker Symbol NVS |
Financial Performance
In 2020, Novartis's revenue was $49.90 billion, an increase of 2.51% compared to the previous year's $48.68 billion. Earnings were $8.07 billion, a decrease of -31.20%.
Analyst Forecasts
According to 5 analysts, the average rating for Novartis stock is "Strong Buy." The 12-month stock price forecast is 105.13, which is an increase of 13.42% from the latest price.